Mirai Tech City

A month in Kobe, October 2026. A few hundred founders, researchers, and clinicians building the scaffolding for the future of biotech.

[Mirai Tech City @MiraiTechCity]

Summit II is this weekend in Kobe.

Aubrey de Grey, Marian Goodell, Prof. Masataka Watanabe, Mac Davis, Rob Claar, Irit Rappley, Julie Ying Baron, Matt Scholz.

Demo Day Monday. 24–26 Oct. https://t.co/TpKcVxkXna

[Mirai Tech City @MiraiTechCity]

With a touch of 🇯🇵

[Probabilistic Biology @prob_bio]

A bit of a tease.

Made in Boston, USA

[Mirai Tech City @MiraiTechCity]

@cremieuxrecueil Come back soon!!

[Mirai Tech City @MiraiTechCity]

@akarlin In 50 years this will be retro and cool. You don’t get the long term investment.

[Mirai Tech City @MiraiTechCity]

@realNathanCheng thank you for hosting LBF day!

Hope we can do a full cohort in Japan soon!

[Mirai Tech City @MiraiTechCity]

@aubreydegrey first time speaking in Japan ✅

Will share the videos soon 👀

[Mirai Tech City @MiraiTechCity]

3 days to Demo Day. 26 October at Orbis Hall, Kobe Fashion Museum. See what the next generation of longevity and biotech looks like: Tickets: https://t.co/TpKcVxkXna

[Mirai Tech City @MiraiTechCity]

Summit II starts tomorrow in Kobe.

Sunday: Prof. Masataka Watanabe on "Digital Immortality via Seamless Mind Uploading and AI Replacement of Damaged Brain Circuitry".

Last tickets: https://t.co/TpKcVxkXna

[Mirai Tech City @MiraiTechCity]

2 days to Summit II: From East to West, Bridging the Longevity Gap, 24–25 October in Kobe. Tickets: https://t.co/TpKcVxkXna

[Mirai Tech City @MiraiTechCity]

Day 1 of Summit I. Thank you to our Saturday speakers @HayanoMotoshi @EleanorSheekey @bluemoon_yuichi @felix_oen @HeckerLouise @FoodLiesOrg @DeryaTR_ @abeyoando_jp @Muse_Bio @shojinmeat @ss_f_official @RIKEN_BDR @KobeU_Global

Summit II: 24 to 26 Oct. https://t.co/TpKcVxkXna

[Mirai Tech City @MiraiTechCity]

What’s on the line at Demo Day. 🏆

On Monday 26 October at Orbis Hall in Kobe, the companies building through Mirai Tech City pitch for these awards:

Come and see who takes them home 👇 https://t.co/e9GnfT5tA1

#MiraiTechCity #DemoDay #Startups #Longevity #Biotech #Kobe #Japan

[Mirai Tech City @MiraiTechCity]

Summit II, Day 2. Sunday 25 October, Kobe.

@bettslacroix @watanabemasata @mariangoodell @longevion @patrissimo @toddjapan @EleanorSheekey @danburonline @realNathanCheng @PedroHenriched @GraniteBio @thatmre @MinicircleDNA

Registration closes Fri 23 Oct. https://t.co/TpKcVxkXna

[Mirai Tech City @MiraiTechCity]

Mirai Tech City wouldn’t be possible without the partners backing longevity, biotech and medtech in Kobe this October.

👇 https://t.co/e9GnfT5tA1

#MiraiTechCity #Longevity #Biotech #Medtech #Kobe #Japan

[Mirai Tech City @MiraiTechCity]

Summit II, Day 1. Saturday 24 October, Kobe.

@aubreydegrey @cordeiro @adamgries @rieglobe @okw @julieyingbaron @OisinBio @AntlerJapan @LongevityEVF

Registration closes Fri 23 Oct. https://t.co/TpKcVxkXna

[Mirai Tech City @MiraiTechCity]

What can the oldest humans alive teach us about ageing?

Natalie S. Coles de Grey (LEV Foundation): "Research and prospects of supercentenarian data"

Summit II, Sat 24 Oct, Kobe. https://t.co/TpKcVxkXna

[Mirai Tech City @MiraiTechCity]

Day 2 of Summit I in Kobe. Thank you to our Sunday speakers @thatmre @devsodhi @j_n_justice @TaylorCapito @MinicircleDNA @AMED_officialGL @xprize @KobeU_Global

Summit II and Demo Day: 24 to 26 Oct. https://t.co/TpKcVxkXna

[Mirai Tech City @MiraiTechCity]

Sat 24 Oct. Aubrey de Grey opens Summit II in Kobe:

"RMR1 was a qualified win: what combining four rejuvenation therapies did, and what RMR2 does next"

https://t.co/TpKcVxkXna

[Mirai Tech City @MiraiTechCity]

Japan’s national insurance covers 70–90% of healthcare costs, with a monthly cap on patient payments. Market structure matters as much as science.

[Mirai Tech City @MiraiTechCity]

In Japan, eligible regenerative-medicine products can reach a self-pay market after Phase 1 safety data. If you have safety data and no clear revenue path, look again.

[Mirai Tech City @MiraiTechCity]

A therapy built for one patient’s mutation cannot run a thousand-patient trial. Japan’s N-of-1 ecosystem offers another route. If you’re building personalised medicine, this is the market to understand: https://t.co/JiYy7D3t3T